Live Breaking News & Updates on Company Biologics

Stay updated with breaking news from Company biologics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Catalent, Inc. Reports Second Quarter Fiscal 2024 Results

Q2 24 net revenue of $1.03 billion decreased 10% as reported, or 11% in constant currency, compared to Q2 23.

Q2 24 net revenue, excluding COVID-related revenue of ~$260 million in Q2’23 and. ....

United States , New Jersey , Alessandro Maselli , Catalent Biomodalities , Novo Holdings , Company Biomodalities , Company Consumer Health , Consumer Health , Consumer Health Segment , Metrics Contract Services , Securities Exchange , Novo Nordisk Foundation , Company Biologics , Catalent Inc , Novo Holding , Chief Executive Officer , Adjusted Net , Net Revenue , Total Net , First Lien Debt , Adjusted Net Income , Net Income , Securities Act , Securities Exchange Act , Annual Report , Quarterly Reports ,